1-(10-undecenyl)-3,7-dimethylxanthine | 156918-64-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-(10-undecenyl)-3,7-dimethylxanthine
• 英文别名: 3,7-dimethyl-1-undec-10-enylpurine-2,6-dione
• CAS: 156918-64-8
• 化学式: C₁₈H₂₈N₄O₂
• 分子量: 332.446
• InChiKey: XUEJQUFGGVXJIA-UHFFFAOYSA-N

物化性质

• 沸点：
  502.5±42.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(10-undecenyl)-3,7-dimethylxanthine 以76的产率得到1-(10, 11-dihydroxyundecanyl)-3,7-dimethylxanthine
  参考文献：
  名称：

  Cell signaling inhibitors

  摘要：

  治疗化合物的化学式为：(X)j-(非环核心基团)，其中j为整数，范围为1到3，核心基团为非环状，X为拉丁混合物、R或S对映体、溶剂化物、水合物或盐：##STR1## *C为手性碳原子，n为整数，范围为1到4（最好为1到3），(CH.sub.2).sub.n的一个或多个碳原子可能被酮基或羟基取代，m为整数，范围为1到14。独立地，R.sub.1和R.sub.2可能是氢、直链或支链烷烃或烯烃，长度最多为12个碳原子，或--(CH.sub.2).sub.w R.sub.5，其中w为整数，范围为2到14，R.sub.5为单、双或三取代或未取代的芳基，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基。或共同，R.sub.1和R.sub.2形成一个取代或未取代的、饱和或不饱和的杂环基团，碳原子数为4到8，其中N为杂原子。R.sub.3为氢或C.sub.1-3。或者，治疗化合物也可以具有以下化学式：##STR2## 其中R.sub.4为氢、直链或支链烷烃或烯烃，长度最多为8个碳原子，--(CH.sub.2).sub.w R.sub.5，其中w为整数，范围为2到14，R.sub.5为单、双或三取代或未取代的芳基，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基，或取代或未取代的、饱和或不饱和的杂环基团，碳原子数为4到8。r和s独立地为整数，范围为1到4，和不大于5。t为整数，范围为1到14，(CH.sub.2).sub.s或(CH.sub.2).sub.t的一个或多个碳原子可能被酮基或羟基取代。

  公开号：

  US05470878A1
• 作为产物：
  描述：

  可可碱 、 11-氯-1-十一碳烯 在 potassium carbonate 作用下， 以 水 、 二甲基亚砜 为溶剂， 以100%的产率得到1-(10-undecenyl)-3,7-dimethylxanthine
  参考文献：
  名称：

  Manufacture of polyglutamate-therapeutic agent conjugates

  摘要：

  该发明提供了制备聚谷氨酸-治疗剂共轭物的新工艺，用于临床开发和药物使用，以及通过这些工艺制备的聚谷氨酸-治疗剂共轭物。

  公开号：

  US20030054977A1

文献信息

• Substituted amino alcohol compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05641783A1

  公开（公告）日：1997-06-24

  Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

  本发明涉及一些化合物，其具有直链或支链脂肪烃结构的化学式I：##STR1## 在式I中，n为1到4的整数，m为4到20的整数。独立的R.sub.1和R.sub.2是氢，长度为20个碳原子或--(CH.sub.2).sub.w R.sub.5的直链或支链烷基，烯基或炔基。如果R.sub.1或R.sub.2是--(CH.sub.2).sub.w R.sub.5，则w可以是1到20的整数，R.sub.5可以是羟基，卤素，C.sub.1-8烷氧基或取代或未取代的碳环或杂环。或者，R.sub.1和R.sub.2可以共同形成取代或未取代的饱和或不饱和杂环，其具有4到8个碳原子，N是所得杂环的杂原子。R.sub.3可以是氢或C.sub.1-3。在这些化合物中，由R.sub.1或R.sub.2，(CH.sub.2).sub.n和(CH.sub.2).sub.m组成的碳原子总和不超过40。R.sub.4是一个末端基团，包括取代或未取代的氧化或还原的环系统，该环系统具有单个环或两到三个融合的环，一个环包含三到七个环原子。所公开的化合物是有效的抑制细胞刺激产生不良反应的药剂。
• Oxime substituted therapeutic compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05770595A1

  公开（公告）日：1998-06-23

  Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula: CORE MOIETY--(R).sub.j including resolved enantiomers (both syn and anti forms) and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic and R may be selected from among: hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10), alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, and formula I. At least one R has the formula I: --(CH.sub.2).sub.n --C--(R.sub.1).sub.p, I wherein n is an integer from three to twenty; p is two or three; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; =N--OR.sub.2, R.sub.2 being hydrogen or a substitute or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; and --(CH.sub.2).sub.s --C(R.sub.3).sub.t (wherein s is zero or an integer from one to ten, t is two or three, R.sub.3 is hydrogen, halogen, hydroxide, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C(.sub.2-10) alkenyl, cyclic or heterocyclic group, or .dbd.N--OR.sub.2, R.sub.2 being defined above). At least one R.sub.1 or one R.sub.3 is .dbd.N--OR.sub.2, p or t corresponding to the at least one R.sub.1 or one R.sub.3 is two, and a second R.sub.1 or second R.sub.3, bonded to the same --C as the at least one R.sub.1 or one R.sub.3, is other than .dbd.N--OR.sub.2. These disclosed compounds are useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through specific intracellular signaling pathways.

  氧肟取代化合物最好是环状或杂环化合物。氧肟取代化合物及其药物组合物的化学式为：CORE MOIETY--(R).sub.j，包括已分离的对映体（同构体和反构体）和/或非对映异构体、水合物、盐、溶剂合物和它们的混合物。j为1到3的整数，核心基团是非环状或环状的，R可以从以下中选择：氢、卤素、羟基、氨基、取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、环状或杂环基团和式I。至少有一个R的式I为：--(CH.sub.2).sub.n --C--(R.sub.1).sub.p，其中n为3到20的整数，p为2或3，R.sub.1可以从以下中选择：氢、卤素、羟基、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基、环状或杂环基团；=N--OR.sub.2，其中R.sub.2为氢或取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、环状或杂环基团；以及--(CH.sub.2).sub.s --C(R.sub.3).sub.t（其中s为零或1到10的整数，t为2或3，R.sub.3为氢、卤素、羟基、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基、环状或杂环基团，或.dbd.N--OR.sub.2，其中R.sub.2如上所定义）。至少有一个R.sub.1或一个R.sub.3是.dbd.N--OR.sub.2，对应于至少一个R.sub.1或一个R.sub.3的p或t为2，与至少一个R.sub.1或一个R.sub.3结合的第二个R.sub.1或第二个R.sub.3不是.dbd.N--OR.sub.2。这些披露的化合物对于治疗或预防通过特定细胞内信号通路进行的介导疾病在许多治疗指标中是有用的。
• Method for preparing substituted amino alcohol compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05777117A1

  公开（公告）日：1998-07-07

  Disclosed is a process for preparing compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocyle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

  公开了一种制备具有公式I的直链或支链脂肪族烃结构化合物的过程：##STR1## 在公式I中，n是从一到四的整数，m是从四到二十的整数。独立的，R.sub.1和R.sub.2是氢，长度为二十个碳原子或--（CH.sub.2）.sub.w R.sub.5的直链或支链烷基，烯基或炔基。如果R.sub.1或R.sub.2是--（CH.sub.2）.sub.w R.sub.5，则w可以是从一到二十的整数，R.sub.5可以是羟基，卤素，C.sub.1-8烷氧基或取代或未取代的碳环或杂环。或者，R.sub.1和R.sub.2可以共同形成取代或未取代的，饱和或不饱和的杂环，其具有从四到八个碳原子，N是所得杂环的杂原子。R.sub.3可以是氢或C.sub.1-3。在化合物中，包括R.sub.1或R.sub.2，（CH.sub.2）.sub.n和（CH.sub.2）.sub.m的总碳原子数不超过四十。R.sub.4是一个终端基团，包括一个取代或未取代，氧化或还原的环系统，该环系统具有单个环或两到三个融合的环，一个环包含从三到七个环原子。所公开的化合物是抑制细胞刺激不良反应的有效剂。
• Amino-alcohol substituted cyclic compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05837703A1

  公开（公告）日：1998-11-17

  Therapeutic compounds have the formula: (X)j-(core moiety), j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH.sub.2).sub.m, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkyl or alkenyl of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxyl group.

  治疗化合物的化学式为：(X)j-(核心部分)，其中j为整数，范围为1到3，核心部分包括一个杂环，其具有一个环或两个融合环，每个环有五个或六个环原子，A是核心部分的碳原子，与(CH.sub.2).sub.m的末端碳原子相连，X具有以下结构，X为外消旋体混合物、R或S对映异构体、溶剂化物、水合物或盐：##STR1## *C是手性碳原子，n为整数，范围为1到4（最好为1到3），(CH.sub.2).sub.n的一个或多个碳原子可能被酮基或羟基取代，m为整数，范围为1到14。独立的，R.sub.1和R.sub.2可能是氢、直链或支链烷基或烯基，长度最长为12个碳原子，或--(CH.sub.2).sub.w R.sub.5，其中w为整数，范围为2到14，R.sub.5为单取代、双取代或三取代或未取代的芳基，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基。或者，R.sub.1和R.sub.2共同形成一个取代或未取代的、饱和或不饱和的杂环基团，其具有4到8个碳原子，N为杂原子。R.sub.3为氢或C.sub.1-3。或者，治疗化合物还可以具有以下化学式：##STR2## R.sub.4为氢、直链或支链烷基或烯基，长度最长为8个碳原子，--(CH.sub.2).sub.w R.sub.5，其中w为整数，范围为2到14，R.sub.5为单取代、双取代或三取代或未取代的芳基，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基，或者为取代或未取代的、饱和或不饱和的杂环基团，其具有4到8个碳原子，r和s分别为整数，范围为1到4，其和(r+s)不大于5。t为整数，范围为1到14，(CH.sub.2).sub.s或(CH.sub.2).sub.t的一个或多个碳原子可能被酮基或羟基取代。
• Hydroxyl-containing xanthine compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05780476A1

  公开（公告）日：1998-07-14

  Disclosed are therapeutic compounds having the formula: (R)j - (core moiety), including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

  本发明揭示了具有以下公式的治疗化合物：（R）j-（核心基团），包括已分离的对映体、非对映体、水合物、盐、溶剂化物和其混合物。其中，j为1至3的整数，核心基团可以是非环状的或包含至少一个五至七元环结构，R可以选择从氢、卤素、羟基、氨基、取代或未取代苄基、C.sub.1-6烷基或C.sub.1-6烯基的群中选择，并且至少有一个R具有以下公式I： 其中，n为7至20的整数，X或Y中至少有一个是—OH。另一个不是—OH的X或Y为氢、CH.sub.3—、CH.sub.3—CH.sub.2—、CH.sub.3—(CH.sub.2).sub.2—或(CH.sub.3).sub.2—CH.sub.2—，每个W.sub.1、W.sub.2和W.sub.3独立地为氢、CH.sub.3—、CH.sub.3—CH.sub.2—、CH.sub.3—(CH.sub.2).sub.2—或(CH.sub.3).sub.2—CH.sub.2—。X、Y、W.sub.1、W.sub.2或W.sub.3烷基可以是未取代或取代的羟基、卤素或二甲氨基基团。本发明揭示的化合物及其治疗组合物在治疗由第二信使活性介导的疾病或治疗引起的毒性的患者中有用。